NEW YORK, July 21, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on BG Medicine,
Inc., (NASDAQ: BGMD). Select highlights from the internally
released reports are being made available to the general public
(included below), with access to the entirety of the research
available to new members.
Today, membership is open to readers on a complementary basis at
the following URL: http://www.aciassociation.com/?c=BGMD
Highlights from our BGMD Report include:
- Market availability of ARCHITECT® Galectin-3
assay - In a press release issued on July 6, 2015, BG Medicine, Inc., informed that
ARCHITECT® Galectin-3 assay is now available in the market. The
Company reported that the ARCHITECT Galectin-3 assay is performed
using the Abbott ARCHITECT automated immunoassay analyzer and is
being commercialized through an agreement between BG Medicine and
the global healthcare services provider, Abbott. The United
States Food and Drug Administration (USFDA) already gave a green
signal to the automated blood test.
- Intended Use of the Test -
Elaborating on ARCHITECT Galectin-3 assay's intended use, BG
Medicine informed that this test is used with the ARCHITECT i
System with STAT protocol capability. As per the release, ARCHITECT
Galectin-3 assay is a chemiluminescent microparticle immunoassay
(CMIA) for the quantitative determination of galectin-3 in human
serum and EDTA plasma. Providing safety instructions about the
test, the Company said that the results from the test should be
interpreted along with clinical findings and other laboratory test
results. There is a possibility that in patients with certain type
of cancers, increase levels of galectin-3 may be found in blood.
Likewise, in patients with conditions associated with organ
fibrosis, it is possible that levels of galectin-3 in blood may be
increased.
- How Galectin-3 Aids
Physicians- With the help of galectin-3 testing, it
is possible to identify patient who are at high risk of heart
failure. The test is of great help for the physicians to determine
which patients are at higher risk of hospitalization or death. In
conjunction with clinical evaluation, the test is to be used as an
aid in assessing the prognosis of patients with chronic heart
failure.
- Management's Comments - Commenting on the
development, the M.D., President and CEO of BG Medicine,
Paul R. Sohmer said, "We believe
that the introduction of automated galectin-3 testing will improve
access to galectin-3 testing, shorten turn-around time for delivery
of test results, and, as a result, accelerate adoption of
galectin-3 testing in the United
States."
To find out how this influences our rating on BG Medicine, Inc.,
read the full report in its entirety here:
http://www.aciassociation.com/?c=BGMD
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the CFA®
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com